Absci (ABSI) Non-Current Deffered Revenue (2021 - 2026)

Absci (ABSI) posted Non-Current Deffered Revenue of $641000.0 for Q1 2026, up 47.02% sequentially from $436000.0 in Q4 2025.

Analysis

Absci (ABSI) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends

Absci has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $641000.0 in Q1 2026.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $641000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $641000.0 (changed N/A YoY) and the FY2025 annual result came in at $436000.0, changed N/A from the prior year.
Non-Current Deffered Revenue improved to $641000.0 in Q1 2026 per ABSI's latest filing, from $436000.0 in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $966000.0 in Q4 2023 and troughed at $180000.0 in Q1 2024.
A 4-year average of $555750.0 and a median of $538500.0 in 2025 frame the typical range for Non-Current Deffered Revenue.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Vertex Pharmaceuticals	139.31 Bn	131.46 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.65 Bn	77.66 Bn	3.93 Bn	220.40 Mn
3	Argenx Se	63.46 Bn	58.27 Bn	1.37 Bn	-
4	Moderna	57.94 Bn	52.80 Bn	52.00 Mn	147.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	-
6	BeOne Medicines	39.96 Bn	34.86 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.16 Bn	31.85 Bn	992.69 Mn	-
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	-
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	-
10	Absci	1.39 Bn	1.19 Bn	-	240,000.00

Historic Data

Download Data